PDCD1 and neoplasm: Further, depletion of CD8+, but not CD4+, T cells significantly abolished the anti-tumor activity of the AT406 and anti-PD1 combination treatment (Supplementary Fig. S11I), suggesting the underlying immune killing effect and CD8+ T cell-dependency.